Company: VRCA
Filing Date: 2025-12-23
Form Type: 424B3
Source: 0001193125-25-330986
Chunk: 5

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-23
Form: 424B3
Chunk 5
---
, in certain cases, 9.99%; provided, further that any such increase will not be effective until the 61st day after such
notice is delivered to the Company.

On November 23, 2025, we also entered into a registration rights agreement with the selling
stockholders named herein (the “Registration Rights Agreement”), pursuant to which we agreed to file registration statements under the Securities Act of 1933, as amended, (the “Securities Act”), with the U.S. Securities and
Exchange Commission (the “SEC”), covering the resale of (i) the shares of common stock issued in connection with the Purchase Agreements and (ii) the shares of common stock issuable upon exercise of the Warrants purchased in
connection with the Purchase Agreements no later than 30 days following the closing of the Private Placement.

2

The Offering

| Common stock offered by the selling stockholders | 14,756,230 shares(1) |

| Terms of the offering | Each selling stockholder will determine when and how it will sell the common stock offered in this prospectus, as described in “Plan of Distribution.” |

| Use of Proceeds | We will not receive any proceeds from the sale of the Resale Shares covered by this prospectus. However, we would receive proceeds from any cash exercise of the Pre-Funded Warrants or Common     
 Warrants as follows: (i) if any Pre-Funded Warrants are exercised for cash, the exercise price of $0.0001 per share; and (ii) if any Common Warrants are exercised for cash, the exercise price of 
 $6.315 per share.                                                                                                                                                                                  |

| Risk Factors | See “Risk Factors” on page 4 for a discussion of factors you should carefully consider before deciding to invest in our common stock. |

| Nasdaq Capital Market symbol | VRCA. |

| (1) | Consists of (i) 6,499,826 shares of our common stock, (ii) up to an aggregate of 5,305,164 Pre-Funded Warrant Shares and (iii) up to an aggregate of 2,951,240 Common Warrant Shares held by the selling stockholders named in this prospectus. |

The selling stockholders named in this prospectus may offer and sell up to 14,756,230 shares of our common stock. Our common stock is currently listed on Nasdaq Capital Market under the symbol “VRCA.” Shares of our common stock that may be